AMLX Amylyx Pharmaceuticals, Inc.
Healthcare$13.68+0.74%ClosedMarket Cap: $1.14B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
5.50
P/S
0.00
EV/EBITDA
-6.02
DCF Value
$2.30
FCF Yield
-10.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-55.7%
ROA
-51.1%
ROIC
-57.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-43.8M | $-41.3M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-36.6M | $-33.0M | $— | — |
| FY null | $0.00 | -Infinity% | $-153.3M | $-144.7M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-36.0M | $-34.4M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-42.9M | $-41.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-37.8M | $-35.9M | $— | — |
| Q4 null | $-665.0K | 100.0% | $-40.7M | $-37.5M | $— | — |
| FY null | $87.4M | 51.8% | $-314.7M | $-301.7M | $— | — |
| Q3 null | $416.0K | -94.5% | $-75.7M | $-72.7M | $— | — |
| Q2 null | $-1.0M | 845.5% | $-53.4M | $-72.7M | $— | — |
| Q1 null | $88.6M | -31.3% | $-122.1M | $-118.8M | $— | — |
| Q4 2023 | $108.4M | 91.4% | $1.9M | $4.7M | $0.07 | — |